港股異動 | 利好疊加 亞盛醫藥-B(6855.HK)續升5%創一個月新高
格隆匯11月17日丨亞盛醫藥-B(6855.HK)續升5%,近7日累計漲幅近30%。現報34.4港元創一個月新高,總市值為91億港元。本月初公司宣佈其上市進度最快的重磅產品――奧雷巴替尼的臨牀進展連續第四年入選ASH年會口頭報吿,該產品即將在近期正式獲批上市,其未來市場潛力也預計將在其上市後轉化為公司估值的真金白銀。另外,自11月4日以來公司已連續6日進行回購,合計回購114.17萬股,累計回購金額3151.93萬港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.